If you are looking into stocks that have managed to record substantial gains this morning then it might be a good idea to take a look at the Vascular Biogenics (NASDAQ: VBLT) stock.
This morning the stock is already up by as much as 13% after the independent Data Safety Monitoring Committee (DSMC) published its review with regards to its recurring ovarian cancer treatment product VB 111. The review in question was in relation to the OVAL Phase 3 study of the product and the findings were positive.
The committee found that the product did not display any safety problems and went on to recommend the continuation of the upcoming steps as planned by Vascular Biogenics. These are significantly positive developments and hence, it is no surprise that the VBLT stock is in focus among investors this morning. It has also been announced that the next review from the DSMC is going to be announced at some point during the third quarter of the year.